Side-by-side comparison of AI visibility scores, market position, and capabilities
Veterinary data analytics and client retention platform identifying at-risk patients due for preventive care. Montreal-based; founded 2015;
VetSuccess is a Montreal-based veterinary data analytics and client retention platform that helps veterinary clinics and corporate veterinary groups analyze practice performance data, identify at-risk patients due for preventive care, and automate targeted client communication to improve retention and grow revenue. Founded in 2015, VetSuccess built its platform on a core veterinary insight: the gap between how frequently pets should receive preventive care and how frequently they actually visit the clinic represents a significant and recoverable revenue opportunity for veterinary practices. By analyzing each clinic's patient database against species-specific care protocols, VetSuccess identifies patients overdue for wellness exams, vaccinations, dental cleanings, and parasite prevention—and automates personalized reminder campaigns to bring them back.\n\nVetSuccess's analytics layer provides veterinary practice owners and managers with benchmarked performance metrics covering active client counts, average transaction value, compliance rates for key services, and retention cohort analysis. This data-driven view allows practices to understand not just what happened last month but how their performance trends compare to regional and national benchmarks, identifying specific service lines or client segments where improvement opportunities exist. The platform's corporate dashboard tier serves multi-location veterinary groups and corporate consolidators that need consistent analytics and benchmarking across dozens of practices.\n\nVetSuccess has built a particular strength in the corporate veterinary market, where large veterinary groups and private equity-backed consolidators require standardized performance management across their clinic portfolios. The company serves clients across Canada and the United States and has integrated its platform with major veterinary practice management systems including IDEXX Cornerstone, AVImark, and ezyVet. VetSuccess competes with Covetrus, Rapport, and Vet Hero in the veterinary client communication and analytics market, differentiating on the depth of its analytics and its strong corporate veterinary customer segment.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.